Trial reportJournal of palliative medicine2026
Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial.
Trial report in Journal of palliative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveSpiritual distress is common in those with metastatic cancer. We evaluated the sustained effects of an empirically anchored 6-week psychoeducation program, Growing Resilience And CouragE (GRACE), on spiritual well-being, quality of life, and psychosocial symptoms.
methodsPrimary and secondary outcomes were assessed at baseline (T0), immediately after GRACE (T1), 1 month after GRACE (T2), and 6 months later (T3). Intervention and waitlist control groups (from the randomized clinical trial) were combined for this analysis. A generalized additive model for location, scale, and shape was used.
resultsData from 54 women with metastatic breast cancer who received GRACE were analyzed. All outcomes (spiritual well-being, quality of life, and psychosocial symptoms) significantly improved at T1, T2, and T3 compared to baseline (
conclusionGRACE is beneficial for the spiritual well-being, quality of life, and psychosocial well-being of women with metastatic breast cancer, and these benefits appear to be sustained at 6 months post-intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.